- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Lymphoma, Colorectal Cancer
- Interventions
- ASSIST phone application
- Other
- Lead sponsor
- Patrick C. Johnson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 2,745
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- warfarin, Dabigatran dose 1, Dabigatran dose 2
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 374
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
- Conditions
- Orthostatic Hypotension, Spinal Cord Injuries
- Interventions
- 1.25 mg enalaprilat IV, Head up tilt (HUT)
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- IPP-201101
- Drug
- Lead sponsor
- ImmuPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Leandro, California • Aventura, Florida + 1 more
- Conditions
- Critical Illness, Sepsis, Respiratory Insufficiency
- Interventions
- Glutamine
- Drug
- Lead sponsor
- Christiana Care Health Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Mosunetuzumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Anniston, Alabama
- Conditions
- Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Stereotactic Ablative Radiotherapy, Systemic Therapy
- Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 80 more
- Conditions
- Primary Systemic Amyloidosis
- Interventions
- 4'-iodo-4'-deoxydoxorubicin, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Nelfinavir
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • Manhasset, New York + 2 more
- Conditions
- Follicular Lymphoma
- Interventions
- Golcadomide, Rituximab, Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone, Bendamustine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 25 more
- Conditions
- Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
- Interventions
- Bocidelpar, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- SIRS, Sepsis
- Interventions
- Not listed
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Lupus Arthritis, Systemic Lupus Erythematosus
- Interventions
- AMG 557, Matching Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Leandro, California • Danbury, Connecticut + 1 more
- Conditions
- Stage IV Melanoma
- Interventions
- Disulfiram (DSF)
- Drug
- Lead sponsor
- John P. Fruehauf
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- Human immune globulin intravenous (IGIV)
- Biological
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Knoxville, Tennessee • Powell, Tennessee
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Bevacizumab (Avastin®)
- Drug
- Lead sponsor
- Hanny Al-Samkari, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 11
- States / cities
- Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
- Conditions
- Lupus Erythematosus, Systemic, Lupus Nephritis
- Interventions
- CTLA4-IgG4m (RG2077), Cyclophosphamide
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- ANCA Associated Vasculitis
- Interventions
- ENUMERATION OF CD5+ B Cells
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
- Interventions
- Physical examination, Electrocardiogram, SF-36 questionnaire, Clinical laboratory evaluations - Serology, Clinical laboratory evaluations - Biochemistry, Clinical laboratory evaluations - Hematology, Pregnancy Test, Urinalysis, SLE activity evaluation, SLE biomarker profiling, Cytokines and chemokine profiling, single dose of UC-MSCs, PROMIS instruments
- Diagnostic Test · Other · Biological
- Lead sponsor
- LiveKidney.Bio
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Meningitis, Bacteremia
- Interventions
- thiamine hydrochloride 100 mg, Placebo
- Drug · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Hershey, Pennsylvania
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
- Interventions
- CF-301, Placebo
- Biological · Drug
- Lead sponsor
- ContraFect
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
- Conditions
- Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
- Interventions
- KYV-101
- Drug
- Lead sponsor
- Kyverna Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2041
- U.S. locations
- 1
- States / cities
- Denver, Colorado